Summit Therapeutics is a small-cap biotech company with two drugs in clinical trials at either end of the new drugs space: a low risk, lower reward antibiotic and a high risk, higher reward Duchenne Muscular Dystrophy cure. Does this make it an ideal biotech investment? Megan Boxall investigates.
Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities.
Investors' Chronicle is a service by the Financial Times.
Hosted on Acast. See acast.com/privacy for more information.
